Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Kedrion-Growth-10pc

More Like This

PR Newswire associated0

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism

PR Newswire associated0

Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care

Keymed Biosciences Announces 2025 Annual Results and Business Updates

Keymed Biosciences Announces 2026 H1 Results and Business Updates

PR Newswire associated0

Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030

Business Wire logo

Chiesi Group Delivers Solid H1 2026 Performance, Combining Growth, Continued Investment in Innovation and Positive Economic Impact Across Communities

ACCESS Newswire logo

Gedeon Richter Highlights Expanding Biosimilars Portfolio and Scientific Engagement at EULAR 2026

Calliditas Therapeutics provides business update ahead of JP Morgan conference